The anti‐breast cancer potential of indole/isatin hybrids
Archiv der Pharmazie · 2023
DOI: 10.1002/ardp.202300402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Archiv der Pharmazie, 2023. Verfasst von Ruo Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Isatin, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 126 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Breast cancer (BC) is one of the most prevalent malignancies and the major contributor to cancer mortality in women globally, with a high degree of heterogeneity and a dismal prognosis. As drug resistance is responsible for most BC fatalities and advanced BC is currently considered incurable, finding innovative anti‐BC chemotherapeutics is urgently required. Indole and its analog isatin (indole‐1 H ‐2,3‐dione) are prominent pharmacophores in the development of novel medications, and their derivatives exhibit strong anticancer activities, also against BC. In particular, indole/isatin hybrids exhibit significant potency against BC including multidrug‐resistant forms and excellent selectivity by influencing a variety of biological targets associated with the disease, supplying helpful building blocks for the identification of potential new BC treatment options. This review includes articles from 2020 to the present and provides insights into the in vitro and in vivo anti‐BC potential, molecular mechanisms, and structure–activity relationships (SARs) of indole/isatin hybrids that may be helpful in the development of innovative anti‐BC chemotherapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Laboratory of Molecule Synthesis and Function Discovery (Fujian Province University), Department of Chemistry, Fuzhou University, Fuzhou, China.
ORCID-Profile: Ruo Wang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, R., Huang, R., Yuan, Y., Wang, Z., & Shen, K. (2023). The anti‐breast cancer potential of indole/isatin hybrids. Archiv der Pharmazie. https://doi.org/10.1002/ardp.202300402
Vancouver
Wang R, Huang R, Yuan Y, Wang Z, Shen K. The anti‐breast cancer potential of indole/isatin hybrids. Archiv der Pharmazie. 2023. doi:10.1002/ardp.202300402
BibTeX
@article{Wang2023,
author = {Wang, Ruo and Huang, Renhong and Yuan, Yaofeng and Wang, Zheng and Shen, Kunwei},
title = {The anti‐breast cancer potential of indole/isatin hybrids},
journal = {Archiv der Pharmazie},
year = {2023},
doi = {10.1002/ardp.202300402}
}
EUVIMED